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Abstract
Objective: Growth retardation in children with β-thalassemia major is multifactorial. Some etiologies described for this
condition are hemochromatosis, disturbed growth hormone (GH) / insulin growth factor-1 (IGF-1) axis, undernutrition and
hypermetabolism. It has also been proven that growth retardation is present in β-thalassemia major children despite 
regular transfusion and chelation. Our aim was to evaluate the level of IGF-1 in β-thalassemia minor subjects and 
compare it with that in healthy children. 
Material and Methods: Fifty children aged 6 months to 15 years with β-thalassemia minor (32 males, 18 females) and 50
age- and sex-matched normal healthy children were selected. Medical history was taken and complete physical examination
was done in each case; IGF-1 level was checked in all cases. This study was done in Shiraz, southern Iran, during 2005.
Results: IGF-1 levels were significantly lower in β-thalassemia minor children than normal children (P = 0.015). This result
demonstrates that some etiologies of growth failure in β-thalassemia major other than those described to date can exist,
which may be shared with β-thalassemia minor in feature or may be transformed by genes that are either expressed or not.
Conclusion: We conclude that in addition to that observed in β-thalassemia major, IGF-1 level is also decreased in 
β-thalassemia minor, and these two may have similar etiologies. (Turk J Hematol 2008; 25: 136-9)
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Özet
Amaç: Beta-talasemi majörlü çocuklarda büyüme gecikmesi, hematokromatoz, büyüme hormonu (GH)/ insülin büyüme
faktörü-1 (IGF-1) ekseninin bozulmas›, yetersiz beslenme ve hipermetabolizma gibi multifaktöriyel bir durumdur. Beta
talasemi majörlü çocuklarda büyüme gecikmesinin düzenli transfüzyon ve ﬂelasyona ra¤men mevcut oldu¤u da
kan›tlanm›ﬂt›r. Amac›m›z β-talasemi minörlü olgularda IGF-1 seviyesini de¤erlendirmek ve bunu sa¤l›kl› çocuklardakiyle
karﬂ›laﬂt›rmakt›r. 
Gereç ve Yöntemler: Erkek, 18 diﬂi ile yaﬂ ve cinsiyet aç›s›ndan eﬂleﬂmiﬂ olan 50 normal çocuk bu çal›ﬂma için seçilmiﬂtir.
Her bir olgu için t›bbi özgeçmiﬂ al›nm›ﬂ ve tam fizik muayene yap›lm›ﬂt›r; tüm vakalarda IGF-1 seviyesi kontrol edilmiﬂtir. Bu
çal›ﬂma, ‹ran’›n güneyindeki ﬁiraz’da 2005 y›l›nda yap›lm›ﬂt›r. Introduction
Beta-thalassemia is one of the most common hereditary 
disorders in the world in which b-chain production is impaired.
Sequelae of this disorder are hyperplastic bone marrow,
increased iron storage and overload, cirrhosis of the liver,
endocrine disturbances, skin hyperpigmentation, cardiac
hemochromatosis, hypersplenism and shortened red cell life [1].
Growth delay is a striking feature of β-thalassemia major.
Insulin-like growth factor-1 (IGF-1) and thyroid hormone appear
to be the major mediators of skeletal growth [2]. Many of the
effects of growth hormone are mediated by IGF-1, which 
circulates in the plasma bound to one of a series of binding 
proteins called IGF binding proteins (IGFBPs). These proteins 
circulate and modify IGF-1 action either as stimulators or
inhibitors [3,4].
It has been shown that IGF-1 and IGFBP-3 response to
growth hormone injection is significantly lower in thalassemia
major patients than normal children, suggesting partial resist-
ance to growth hormone in these children [5,6]. In general, there
is no doubt that growth retardation in β-thalassemia major is
multifactorial. 
Beta thalassemia trait (BTT) is almost invariably asympto-
matic and is characterized by mild anemia, a slightly reduced
hemoglobin level and a marked reduction in mean corpuscular
volume (MCV) and mean corpuscular hemoglobin (MCH). 
BTT is one of the most prevalent genetic disorders in
Mediterranean countries. Close to 10% of the Iranian population
has BTT according to the place of residence. BTT is most fre-
quent (7-10%) in northern and southern Iran [7,8]. 
We observed that some of the patients that referred to the
Pediatric Endocrinology Clinic due to short stature or poor
weight gain were carriers of β-thalassemia. Therefore, we per-
formed this study in order to investigate any correlation between
IGF-1 level and growth retardation in β-thalassemia minor sub-
jects and to compare its level with that in normal children. 
Materials and Methods
In this case-control study, 50 children aged between 6
months and 15 years with β-thalassemia minor who had referred
to our clinic were randomly selected within a period of six
months during 2005. All of them had received breast milk for at
least one year and none of them had splenomegaly or any other
medical disorder except β-thalassemia minor. Thirty-two were
male and 18 were female. The control group consisted of 50
age- and sex-matched healthy children who came for routine
check-up and who had no nutritional deficiencies and no chron-
ic or systemic disorders; their height and weight were between
the 3rd and 95th percentile for age. Medical history was taken
and complete physical examination was done in each case. We
excluded all patients with familial short stature, constitutional
growth delay, hormone deficiency, malnutrition, and chronic sys-
temic disorders, and included healthy patients with thalassemia
minor. We divided the thalassemia minor patients and controls in
two subgroups as under 5 years and above 5 years. 
Anthropometric parameters of weight and height were
measured in both groups. Other data included hemoglobin (Hb),
MCV, MCH, mean corpuscular hemoglobin concentration
(MCHC), hemoglobin F (HbF) and hemoglobin A2 (HbA2). Their
carrier state was established by complete blood count (CBC),
MCH, MCV, Hb electrophoresis (by citrate agar), HbA2 (by col-
umn chromatography) and HbF (by alkaline denaturation). 
In all cases, after obtaining an informed written consent from
the subjects’ parents, 5 ml of venous blood was withdrawn for
measurement of IGF-1 and serum ferritin. We measured serum
ferritin, serum iron and total iron binding capacity (TIBC) in order
to rule out combined iron deficiency anemia and β-thalassemia
minor. Human IGF-1 was measured by radioimmunoassay (RIA)
employing reagents (Immunotech Co., France). Serum ferritin
was also measured by RIA employing reagents (Orion Co., Orion
Diagnostica Espoo, Finland). 
Data of the 2000 Centers for Disease Control (CDC) growth
chart was used to compare anthropometric measurements of β-
thalassemia minor children with normally accepted weight and
height for age.
Data were presented as mean SD. Statistical analyses were
performed by Mann-Whitney U test to compare IGF-1 concen-
trations in these two groups and using correlation to determine
the relationship between IGF-1 and other variants. P-values less
than 0.05 were considered as significant. This study was done
in Shiraz, southern Iran, and was approved by the medical ethics
committee of Shiraz University of Medical Sciences. 
Results
Beta-thalassemia minor subjects had a mean age of 6.5 ± 3.4
years (range: 6 months to 15 years) and the control group had a
mean age of 6.8 ± 3.4 years (range: 4 months to 14.5 years).
Eight children had combined iron deficiency anemia and
were therefore excluded from the study. Others had normal lev-
els of serum ferritin, serum iron and TIBC. 
IGF-1 level was 61.33 ± 67.64 ng/ml in the beta-thalassemia
minor group and 126.93 ± 156.7 ng/ml in the control group.
IGF-1 level was significantly higher in the control group
(P=0.015). Table 1 shows the data of thalassemia minor patients
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jects under the age of 5 years were 37.3 ± 27.5 ng/ml and 44.5
± 36.1, respectively. This difference was not statistically signifi-
cant (P=0.7). However, the levels of IGF-1 in thalassemia minor
and control subjects in the subgroup above 5 years of age were
77.7 ± 81.4 ng/ml and 188.7 ± 183 ng/ml, respectively, and this
difference was statistically significant (P< 0.05). We found no
effect of sex on hormonal level. 
In comparison with CDC data, height for age was below the
3rd percentile in 10% of thalassemia minor children, while it was
below the 25th percentile in 52% and below the 50th percentile
in 78%. Low IGF-1 was seen in thalassemia minor subjects both
below and above the 3rd percentile, and height below 3rd per-
centile was seen in thalassemia minor subjects both below and
above 5 years of age. Weight for age was below the 3rd per-
centile in 4% of the thalassemia minor patients, while it was below
the 25th percentile in 50% and below the 50th percentile in 78%. 
Discussion
To the best of our knowledge, this is the first report on IGF-
1 levels in β-thalassemia minor cases. In our study, we observed
that IGF-1 was decreased in β-thalassemia minor patients in
comparison with normal children. Previous reports have shown
that children with β-thalassemia major frequently have growth
retardation in the presence of low serum IGF-1 and abnormal
growth hormone [9,10]. 
It has been proven that growth retardation in children with β-
thalassemia major is multifactorial [5,11] and that despite regular
blood transfusions and desferrioxamine treatment, these
patients have growth delay and bone alteration [10-12].
However, there is a state of partial growth hormone insensitivity
at the post-receptor level that can be overcome by supra-phys-
iological doses of exogenous growth hormone [11,13].
In general, β-thalassemia major patients have growth retarda-
tion due to the contribution of lack of pubertal growth spurt and
decreased synthesis of IGF-1, which might be secondary to a dis-
turbed growth hormone/IGF-1 axis and/or undernutrition, proba-
bly due to the hypermetabolic status of these children [14,15].
In this study, we showed that IGF-1 levels are low in carriers
of β-thalassemia gene when compared with normal children. The
limitation of this study is that we could not measure IGFBP-3
because of unavailability of the IGFBP-3 kit. All of the selected tha-
lassemia minor children were healthy without any medical disor-
der. Ten percent of these children had short stature (height for age
below 3rd percentile) and 4% had weight for age below the 3rd
percentile. Similar results obtained here have also been reported
in thalassemia major patients [6,9-11]. This may be due to some
genetic impairment that it shares with β-thalassemia major [16].
Additionally, in another study performed on thalassemia
minor subjects, short stature was significantly more prevalent,
which is similar to that observed in patients with thalassemia
major [16]. There was no difference between IGF-1 levels in both
groups under 5 years of age. Serum IGF-1 concentrations are
highly age-dependent. They are lowest in young children (<5
years of age), the age at which one most wishes to have a sin-
gle diagnostic test 2. 
We think that some etiologies other than those described to
date for growth retardation in β-thalassemia major may exist that
can be transformed by genes, whether expressed or not.
In conclusion, similar to patients with thalassemia major, IGF-
1 levels in β-thalassemia minor children are also lower than in
normal children. 
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Pg: Picogram. g/dl: Gram/deciliter. fL: Femtoliter
Karamifar et al.
Insulin-like growth factor-1 levels in children with β- Thalassemia minor Turk J Hematol 2008; 25: 136-9 13810.  Soliman AT, Elzalabany MM, Mazloum Y, Bedair SM, Ragab MS,
Rogol AD et al. Spontaneous and provoked growth hormone secre-
tion and IGF-1 factor concentration in patients with β-thalassemia
and delayed growth. J Trop Pediatr 1999; 45: 327-37.
11. Low LC, Postel Vinay MC, Kwan EY, Cheung PT. Serum growth
hormone binding protein, IGF-1 and IGFBP-3 in patients with 
β-thalassemia major and the effect of GH treatment. Clin
Endocrinol (Oxf) 1998; 48: 641-6.
12. Sartorio A, Conte G, Conti A, Masala A, Alagna S, Rovasio P et al.
Effects of 12 months rec - GH therapy on bone and collagen
turnover and bone mineral density in GH deficient children with tha-
lassemia major. J Endocrinol Invest 2000; 23: 356-61.
13. Katzos G, Papakostantinou-Athanasiadou E, Athanasiou-Metaxa M,
Harsoulis F. Growth hormone treatment in short children with 
β-thalassemia major. J Pediatr Endocrinol Metab 2000; 13: 163-70.
14. Wu KH, Tsai FJ, Peng CT. Growth hormone (GH) deficiency in
patients with beta- thalassemia major and the efficacy of recombi-
nant GH treatment. Ann Hematol 2003; 82: 637-40.
15. Karydis I, Karagiorga-Lagana M, Nounopoulos C, Tolis G. Basal
and stimulated level of growth hormone, insulin-like growth factor-
1 (IGF-1), IGF-1 binding and IGF-binding proteins in beta-tha-
lassemia major. J Pediatr Endocrinol Metab 2004; 17: 17-25.
16. Karimi M, Karamifar HA. Short stature in beta-thalassemia minor
subjects. Med Sci Monit 2004; 10: CR603-5.
Karamifar et al.
Insulin-like growth factor-1 levels in children with β- Thalassemia minor Turk J Hematol 2008; 25: 136-9 139